33522-03-1

Usage

Uses

It employed as a intermediate for pharmaceutical.

InChI:InChI=1/C6H9NS/c8-5-7-6-3-1-2-4-6/h6H,1-4H2

Upstream product

• 3558-06-3 cyclopentyl tosylate 
• 333-20-0 potassium thioacyanate 
• 75-15-0 carbon disulfide 
• 122058-03-1 diethyl N-cyclopentylphosphoramidate 
• 1003-03-8 Cyclopentamine 
• 463-71-8 thiophosgene 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 
• 5263-57-0 cyclopentyl thiocyanate 

Downstream Products

• 101265-27-4 N-cyclopentyl-N'-(toluene-4-sulfonyl)-thiourea 
• 1027-87-8 N-p-Tolylsulfonyl-N'-cyclopentyl-harnstoff 
• 1092333-14-6 2,9-dimethyl-3,5-diphenylfuro[3,2-g]chromen-7-one n-cyclopentylthiosemicarbazone 
• 39964-27-7 1-cyclopentyl-3-(4-iodophenyl)thiourea 
• 1412407-26-1 C₂₃H₂₇N₅OS 
• 122813-74-5 4-cyclopentyl thiosemicarbazide 
• 1311285-35-4 N-cyclopentyl-5-(4-methoxy-3,5-dimethylphenyl)-1,3,4-thiadiazol-2-amine 
• 79221-23-1 2-(4-cyclohexylthiocarbamoyl-piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline 

Relevant academic research and scientific papers

4-Dimethylaminopyridine-catalyzed synthesis of isothiocyanates from amines and carbon disulfide

Isothiocyanates were synthesized by reactions between primary amines and CS2 in the presence of 4-dimethylaminopyridine as a catalyst and tert-butyl hydroperoxide as an oxidant. Various aryl, benzyl, alkyl, and hydroxyl amines were transformed into the corresponding isothiocyanates in 41–82% yields.

Synthesis method of 2-aminothiazole pyrimidine serving as CDK2 inhibitor

The invention relates to the technical field of organic synthesis and medicines, and particularly discloses a synthesis method of 2-aminothiazole pyrimidine serving as a CDK/2 inhibitor. The synthesismethod comprises the following steps: converting amino into isothiocyanate, reacting the isothiocyanate with primary amine to generate thiourea, and carrying out Hantzsch thiazole synthesis reaction,fluorination reaction and condensation of enaminone and guanidine hydrochloride to form a pyrimidine ring. According to the method, through five steps of reactions, the total yield reaches 35%-48%. The method has the advantages that a traditional fluorination method is replaced by photocatalysis; the yield of the whole process is greatly increased, the yield is increased to 85% from 35% through the fluorination reaction, and compared with a traditional fluorination method in a low-temperature ice salt bath, the method is milder in condition, only needs to be carried out at the room temperature, and is a good process for synthesizing the CDK/2 inhibitor 2-aminothiazole pyrimidine.

Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses

There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64 μM for viruses resistant to pleconaril, a known capsid-binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing. Curing the common cold! A cluster of pyrazolopyrimidines with potent broad-spectrum activity against enteroviruses was discovered. Extensive structure-property relationship analyses led to the identification of 3-(4-trifluoromethyl-phenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine, shown to be a blocker of the viral capsid protein, as a lead compound for drug development with favorable physicochemical, pharmacokinetic, and toxicological properties.

A new efficient synthesis of isothiocyanates from amines using di-tert-butyl dicarbonate

Alkyl and aryl amines are converted smoothly to the corresponding isothiocyanates via the dithiocarbamates in good to excellent yields using di-tert-butyl dicarbonate (Boc2O) and 1-3 mol % of DMAP or DABCO as catalyst. As most of the byproducts are volatile, the work-up involves simple evaporation of the reaction mixture.

The Improved Phosphoramidate Route to Isothiocyanates

Moderate yields of isothiocyanates prepared by the Wadsworth-Emmons approach can be essentially improved when the reaction is carried out in the presence of catalytic amounts of tetrabutylammonium bromide.